Mitsubishi Tanabe looks for HIT with UK launch of danaparoid rival argatroban
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma's (MTP) European subsidiary has launched the direct thrombin inhibitor Exembol (argatroban) in the UK for the treatment of adult patients with heparin-induced thrombocytopenia type II (HIT) who require parenteral antithrombotic therapy.